Free accessResearch articleFirst published online 1997-10
Anti-Human Immunodeficiency Virus Type 1 Activity of R-95288,a Phosphodiester Hexadeoxyribonucleotide Modified by Dibenzyloxybenzyl and Hydroxyethyl Residues at the 5′- and 3′-Ends
The phosphodiester hexadeoxyribonucleotide R-95288 is a potent anti-human immunodeficiency virus type 1 (HIV-1) agent in vitro which consists or a TGGGAG nucleoside sequence with dibenzyloxybenzyl and hydroxyethyl substituents at the 5′- and 3′-ends, respectively. In this study, the antiviral activity of R-95288 against various strains of HIV-1 in vitro was assessed and its mechanism of action was analysed. R-95288 inhibited replication of all strains of HIV-1 used including laboratory strains with the syncytium-inducing (SI) phenotype and clinical isolates with both SI and non-SI (NSI) phenotypes. The 50% inhibitory concentrations (IC50s) were 0.62–18 μg mL−1 (0.21–6.2 μM). R-95288 inhibited the binding and fusion of HIV-1-infected T cells with CD4+ cells. In addition, R-95288 specifically blocked the binding of monoclonal antibodies, recognizing the anti-V3 loop or the CD4-binding site of the virus envelope glycoprotein gp120. Furthermore, the target site of R-95288 within the V3 loop was found in the putative heparin-binding region by binding inhibition assays using various anti-V3 loop antibodies. These results suggest that R-95288 can inhibit various strains of HIV-1, possibly by specific interaction with gp120.
AgatsumaTYamamotoYFurukawaH & NishigakiT (1996) Guanine-rich oligonucleotide modified at the 5′ terminal by dimethoxytrityl residues inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Research31:137–148.
2.
AgatsumaTFurukawaHAbeKKogaRKoizumiMHotodaH & KanekoM (1997) Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a modified oligonucleotide, R-95288. Antiviral Research34:121–130.
3.
BuckheitRWRobertsonJLLackman-SmithCWyattJRVickersTA & EckerDJ (1994) Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS5320). AIDS Research and Human Retroviruses10:1497–1506.
4.
CallebautCKrustBJacototE & HovanessianAG (1993) T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. Science262:2045–2050.
5.
CardinAD & WeintraubHJR (1989) Molecular modelling of protein-glycosaminoglycan interactions. Arteriosclerosis9:21–32.
6.
CordellJMooreJPDeanCJKlassePJWeissRA & McKeatingJA (1991) Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology185:72–79.
7.
DalgleishAGBeverlyPCLClaphamPRCrawfordDHGreavesMF & WeissRA (1984) The CD4 (T4) antigen is an essential component of the receptor for AIDS retrovirus. Nature312:763–766.
8.
DashPLotanIKnappMKandelER & GoeletP (1987) Selective elimination of mRNAs in vivo: complementary oligonucleotides promote RNA degradation by an RNase H-like activity. Proceedings of the National Academy of Sciences, USA84:7896–7900.
9.
DawesJBabaLBillaudE & SamamaM (1986) Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis16:116–122.
10.
FecondoJVPavukNCSilburnKAReadDMMansellASBoydAW & McPheeDA (1993) Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells. AIDS Research and Human Retroviruses9:733–740.
11.
FelberBK & PavlakisGN (1988) A quantitative bioassay for HIV-1 based on trans-activation. Science239:184–187.
12.
FlexnerCBarditch-CrovoPAKornhauserDMFarzadeganHNerhoodLJChaissonREBellKMLorentsenKJHendrixCWPettyBG & LietmanPS (1991) Pharmacokinetics, toxicity and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy35:2544–2550.
13.
FurukawaHMomotaKAgatsumaTYamamotoIKimuraS & ShimadaK (1994) Mechanism of inhibition of HIV-1 infection in vitro by guanine-rich oligonucleotides modified at the 5′ terminal by dimethoxytrityl residue. Nucleic Acids Research22:5621–5627.
14.
FurukawaHMomotaKAgatsumaTYamamotoIKimuraS & ShimadaK (1997) Identification of a phosphodiester hexaoligonucleotide that inhibits HIV-1 infection in vitro upon covalent linkage of its 5′-end with dimethoxytrityl residue. Antisense and Nucleic Acid Drug Development7:167–175.
15.
GruberMFWebbDSGerrardTLMostowskiHSVujcicL & GoldingH (1991) Re-evaluation of the involvement of the adhesion molecules ICAM-1/LFA-1 in syncytia formation of HIV-1-infected subclones of a CEM T-cell leukemic fine. AIDS Research and Human Retroviruses7:45–53.
16.
HammerSM (1996) Advances in antiretroviral therapy and viral load monitoring. AIDS10:S1–S11.
17.
HarropHACoombeDR & RiderCC (1994) Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS8:183–192.
18.
HildrethJE & OrentasRJ (1989) Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science244:1075–1078.
19.
HoDDSarngadharanMGHirschMSSchooleyRTRotaTRKennedyRCChanhTC & SatoVL (1987) Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. Journal of Virology61:2024–2028.
20.
JavaherianKLangloisAJLaRosaGJProfyATBolognesiDPHerlihyWCPutneySD & MatthewsTJ (1990) Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science250:1590–1593.
21.
JavaherianKKhiroyaRQuinlanCBoydJG & HanhamKA (1994) V3-mediated heparin neutralization of HIV type 1. AIDS Research and Human Retroviruses10:1421–1423.
22.
KogaRKoizumiMHotodaHMomotaKOhmineTFurukawaHNishigakiTKosakaT & KanekoM (1996) Biologically active oligonucleotides – VI: structure-activity relationships of anti-HIV-1 hexadeoxyribonucleotides bearing 3′- and 5′-end-modifications. Antiviral Research (Supplement) 30:47, A32.
23.
KootMVosAHKeetRPde-GoedeREDercksenMWTerpstraFGCoutinhoRAMiedemaF & TersmetteM (1992) HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS6:49–54.
24.
LamanJDSchellekensMMAbaciogluYHLewisGKTersmetteMFouchierRALangedijkJPClaassenE & BoersmaWT (1992) Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptide from the gp120 third variable domain. Journal of Virology66:1823–1831.
25.
LambertDMBartusAVBratby-AndersCLearyJJDreyerGBMetcalfBW & PettewaySRJr (1993) Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different models of HIV-1 infection. Antiviral Research21:327–342.
26.
LarderBADarbyG & RichmanDD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science243:1731–1734.
27.
LedermanSSullivanGBenimetskayaLLowyILandKKhaledZClearyAMYakubovL & SteinCA (1996) Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independently of G-tetrad formation. Antisense and Nucleic Acid Drug Development6:281–289.
28.
LorentzenKJHendrixCWCollinsJMKornhauserDMPettyBGKleckerRWFlexnerCExkelRH & LietmanPS (1989) Dextran sulfate is poorly absorbed after oral administration. Annals of Internal Medicine111:561–566.
29.
McKeatingJACordellJDeanCJ & BalfeP (1992a) Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology191:732–742.
30.
McKeatingJAThaliMFurmanCKarwowskaSGornyMKCordellJZollaPSSodroskiJ & WeissRA (1992b) Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology190:134–142.
31.
McKeatingJAShottonCCordellJGrahamSBalfePSullivanNCharlesMPageMBolmstedtAOlofssonSKaymanSCWuZPinterADeanCSodroskiJ & WeissRA (1993) Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. Journal of Virology67:4932–4944.
32.
MooreJP & JarrettRF (1988) ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Research and Human Retroviruses4:369–379.
33.
MuesingMASmithDHCabradillaCDBenetonCVLaskyLA & CaponDJ (1985) Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature313:450–458.
34.
MusterTSteindlFPurtscherMTrkolaAKlimaAHimmlerGRukerF & KatingerH (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology67:6642–6647.
35.
OhnoTTeradaMYonedaYSheaKWChambersRFStrokaDMNakamuraM & KufeDW (1991) A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gpl20. Proceedings of the National Academy of Sciences, USA88:10726–10729.
36.
OjwangJOBuckheitRWPommierYMazumderADe VreeseKEsteJAReymanDPallanschLALackmann-SmithCWallaceTLDe ClercqEMcGrathMS & RandoRF (1995) T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy39:2426–2435.
37.
PauwelsRBalzariniJBabaMSnoeckRScholsDHerdewijnPDesmyterJ & De ClercqE (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods20:309–321.
38.
ScholsDPauwelsRDesmyterJ & De ClercqE (1990) Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gpl20 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology175:556–561.
39.
St ClairMHMartinJLTudor-WilliamsGBachMCVavroCLKingDMKellamPKempSD & LarderBA (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science253:1557–1559.
40.
SteinCANeckersLMNairBCMumbauerSHokeG & PalR (1991) Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gpl20 to CD4. Journal of Acquired Immune Deficiency Syndromes4:686–693.
41.
SteinCAClearyAMYakubovL & LedermanS (1993) Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (V3) of human immunodeficiency virus type 1 gpl20. Antisense Research and Development: 19–31.
42.
ValentinALundinKPatarroyoM & AsjoB (1990) The leukocyte adhesion glycoprotein CD18 participates in HIV-1-induced syncytia formation in monocytoid and T cells. Journal of Immunology144:934–937.
43.
VellaS (1995) Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology10:S58–S61.
44.
VeroneseFDRahmanRPalRBoyerCRomanoJKalyanaramanVSNairBCGalloRC & SargadharanMG (1992) Delineation of immunoreactive, conserved regions in the external glycoprotein of the human immunodeficiency virus type 1. AIDS Research and Human Retroviruses8:1125–1132.
45.
WatanabeTHanzawaHHaruyamaHKoizumiM & KanekoM (1996) Analysis of stereo structure of anti-HIV-1 oligonucleotide, S-1443 (R-95288). Seikagaku68:941.
46.
WyattJRVickersTARobersonJLBuckheitRJKlimkaitTDeBaetsEDavisPWRaynerBImbachJL & EckerDJ (1994) Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proceedings of the National Academy of Sciences, USA91:1356–1360.
